Paschim Vihar, Delhi
GST No. 07AOFPC0081E1ZK
Approx. Rs 30,500 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Type | Box |
Packaging Size | 21 Film Coated Tablets/Box |
Treatment | Metastatic breast cancer (For Oral Use) |
Prescription/Non prescription | Prescription |
Brand | Kryxana |
Form | Tablet |
Strength | 200 mg |
Approx. Rs 200 / BoxGet Latest Price
Product BrochureProduct Details:Strength | 50 mg |
Packaging Size | 3x10 Tablet/Blister |
Brand | Ablu |
Composition | Bicalutamide |
Manufacturer | Neon |
Treatment | Prostate cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Approx. Rs 40,000 / BoxGet Latest Price
Product BrochureProduct Details:Strength | 40 mg |
Packaging Size | 4x28 Capsules |
Brand | Bdenza |
Composition | Enzalutamide |
Treatment | Prostate Gland Cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Approx. Rs 3,500 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Size | 30 Tablets/Box |
Composition | Erlotinib Hydrochloride |
Manufacturer | DM Cology |
Treatment | Non-Small Cell Lung Cancer,Pancreatic cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Strength | 100 mg |
Approx. Rs 4,500 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Size | 30 Tablet/Box |
Brand | Erlonat |
Composition | Erlotinib |
Manufacturer | Natco |
Treatment | Lung Cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Strength | 150 mg |
Note :- Erlonat Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug.
Approx. Rs 3,800 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Size | 30 Tablets/Box |
Brand | Cipla |
Composition | Erlotinib |
Treatment | Lung, Pancreatic Cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Strength | 100 mg |
Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR, also known as HER1) tyrosine kinase inhibitor. Erlotinib potently inhibits the intracellular phosphorylation of EGFR. EGFR is expressed on the cell surface of normal cells and cancer cells. In non-clinical models, inhibition of EGFR phosphotyrosine results in cell stasis and/or death. Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized.
EGFR mutations may lead to constitutive activation of anti-apoptotic and proliferation signalling pathways. The potent effectiveness of erlotinib in blocking EGFR-mediated signalling in these EGFR mutation-positive tumours is attributed to the tight binding of erlotinib to the ATP-binding site in the mutated kinase domain of the EGFR. Due to the blocking of downstream signalling, the proliferation of cells is stopped and cell death is induced through the intrinsic apoptotic pathway. Tumour regression is observed in mouse models of enforced expression of these EGFR-activating mutations.
Absorption and Distribution
Metabolism and Excretion
Approx. Rs 1,300 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Size | 10 Tablets/Box |
Brand | Gefticip |
Composition | Gefitinib |
Manufacturer | Cipla |
Treatment | Non Small Cell Lung Cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Strength | 250 mg |
The mechanism of the clinical antitumour action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK).
The epidermal growth factor (EGF) and its receptor (EGFR ) have been identified as key drivers in the process of cell growth and proliferation for normal and cancer cells. EGFR activating mutation within a cancer cell is an important factor in promotion of tumour cell growth, blocking of apoptosis, increasing the production of angiogenic factors and facilitating the processes of metastasis.
Gefitinib is a selective small molecule inhibitor of the epidermal growth factor receptor tyrosine kinase and is an effective treatment for patients with tumours with activating mutations of the EGFR tyrosine kinase domain regardless of line of therapy. No clinically relevant activity has been shown in patients with known EGFR mutation-negative tumours.
Approx. Rs 2,500 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Size | 3x10 Tablet/Box |
Brand | Endace |
Composition | Megestrol Acetate |
Manufacturer | Samarth Life Science Pvt Ltd |
Treatment | Breast Cancer,Endometrial Cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Strength | 160 mg |
Approx. Rs 4,000 / BoxGet Latest Price
Product BrochureProduct Details:Packaging Size | 30 Tablets/Box |
Brand | Cipla |
Composition | Erlocip |
Treatment | Lung, Pancreatic Cancer |
Prescription/Non prescription | Prescription |
Form | Tablet |
Strength | 150 mg |
Erlotinib is an epidermal growth factor receptor/human epidermal growth factor receptor type 1 (EGFR, also known as HER1) tyrosine kinase inhibitor. Erlotinib potently inhibits the intracellular phosphorylation of EGFR. EGFR is expressed on the cell surface of normal cells and cancer cells. In non-clinical models, inhibition of EGFR phosphotyrosine results in cell stasis and/or death. Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized.
EGFR mutations may lead to constitutive activation of anti-apoptotic and proliferation signalling pathways. The potent effectiveness of erlotinib in blocking EGFR-mediated signalling in these EGFR mutation-positive tumours is attributed to the tight binding of erlotinib to the ATP-binding site in the mutated kinase domain of the EGFR. Due to the blocking of downstream signalling, the proliferation of cells is stopped and cell death is induced through the intrinsic apoptotic pathway. Tumour regression is observed in mouse models of enforced expression of these EGFR-activating mutations.
Absorption and Distribution
Metabolism and Excretion
Approx. Rs 3,000 / BoxGet Latest Price
Product BrochureProduct Details:Minimum Order Quantity | 1 Box |
Packaging Size | 30 Tablet / Box |
Brand | Cipla |
Manufacturer | Cipla |
Treatment | Anti Cancer Tablet |
Prescription/Non prescription | Prescription |
Form | Tablet |
Country of Origin | Made in India |
Approx. Rs 300 / BoxGet Latest Price
Product BrochureProduct Details:Dose/Strength | 500 mg |
Manufacturer | Cipla |
Packaging Size | 10 Tablets |
Brand | Armotraz |
Prescription/Non prescription | Prescription |
Treatment | Cancer |
Explore More Products
© Tavisha Biotech. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited